Key Points GraniteShares sold its entire stake of Trinity Capital during the fourth quarter. The fund reported that its holdings decreased by 212,465 shares worth $3.29 million. The position was previously 1.9% of the fund's AUM as of the prior quarter. These 10 stocks could mint the next wave of millionaires › GraniteShares Advisors LLC fully exited its position in Trinity Capital (NASDAQ:TRIN), selling 212,465 shares worth an estimated $3.29 million in the fourth quarter. What happened Accor ...

Core Insights - Ares Capital Corporation (ARCC) and Hercules Capital, Inc. (HTGC) are prominent Business Development Companies (BDCs) that focus on income-oriented investments, primarily providing senior secured and structured debt financing to middle-market U.S. companies, with revenues largely derived from interest income [1][3] Group 1: Ares Capital Corporation (ARCC) - ARCC has a diversified investment portfolio, with corporate borrower investments ranging from $30 million to $500 million and power generation projects between $10 million and $200 million, focusing on senior secured debt [4] - In the first nine months of 2025, ARCC experienced year-over-year growth in total investment income, driven by increased interest income, capital structuring service fees, and other income, alongside decent portfolio exits and gross commitments [5] - From 2019 to 2024, ARCC's total investment income had a compound annual growth rate (CAGR) of 14.4%, with gross investment commitments of $15.1 billion in 2024 and $6.7 billion in 2020 [6] - As of September 30, 2025, ARCC's investment portfolio included 23.2% in software & services and 11.9% in healthcare equipment & services, although exposure to tariffs may pose risks to certain industries [7][10] - Analysts project a decline in ARCC's earnings, with estimates indicating a 14.2% drop for 2025 and a 2.2% decline for 2026, reflecting bearish sentiments [13][21] Group 2: Hercules Capital, Inc. (HTGC) - HTGC's investments typically range from $15 million to $40 million, focusing on structured debt with warrants and targeting high-growth technology and life sciences companies [8] - In the first nine months of 2025, HTGC reported growth in total investment income and an increase in gross new debt and equity commitments, with a CAGR of 13% in total investment income from 2019 to 2024 [9][11] - As of September 30, 2025, HTGC's investment portfolio was valued at $4.31 billion, with 35.3% in software companies and 23% in drug discovery & development, positioning it well against tariff impacts [12][20] - Analysts are more optimistic about HTGC's earnings, with a projected 4% decline for 2025 but a 4.9% growth for 2026, indicating upward revisions in estimates [14][15] - HTGC's stock is trading at a lower forward price-to-earnings (P/E) ratio of 9.08X compared to ARCC's 10.33X, suggesting it is more attractively valued [17][20] Group 3: Comparative Analysis - In the past six months, HTGC shares declined by 1.7%, while ARCC shares fell by 10.4%, against an industry decline of 9.8% [15] - The operating environment is becoming more favorable, with HTGC better positioned for long-term growth due to its focus on high-growth sectors and rising investment commitments [20][21] - ARCC's broader industry exposure may expose it to tariff-related risks, while HTGC's specialization and stronger earnings trajectory make it a more compelling investment choice for long-term returns [21][22]

Group 1: Overview of Ares Capital Corporation (ARCC) - Ares Capital focuses on middle-market firms across various industries, providing debt financing ranging from $30 million to $500 million [6][9] - As of March 31, 2025, ARCC had a diversified investment portfolio of $27.1 billion across 566 portfolio companies, with significant investments in software & services (24%) and healthcare equipment & services (13%) [9][12] - In Q1 2025, ARCC reported a 4.4% year-over-year growth in total investment income, driven by increased interest income, but faced lower portfolio exits and gross commitments [7][12] Group 2: Overview of Hercules Capital, Inc. (HTGC) - Hercules Capital specializes in venture debt, targeting high-growth technology and life sciences sectors, with investments generally ranging from $15 million to $40 million [15][20] - As of March 31, 2025, HTGC had an investment portfolio of $3.9 billion, with 32% in software companies and 29% in drug discovery & development [20][23] - In Q1 2025, HTGC experienced a 2% decline in total investment income but recorded a rise in gross new debt and equity commitments [16][23] Group 3: Financial Performance and Growth Outlook - Ares Capital's total investment income has seen a CAGR of 14.4% over the last five years, with significant gross investment commitments in recent years [8][12] - Hercules Capital's total investment income has a CAGR of 12.1% over the last decade, with increasing demand for customized financing expected to drive future growth [16][17] - Analysts have revised earnings estimates downward for ARCC, indicating a 12% decline for 2025, while HTGC's earnings are expected to decline by 4% in 2025 but grow by 5.9% in 2026 [26][38] Group 4: Valuation and Comparison - Ares Capital is currently trading at a forward P/E of 10.54X, higher than its five-year median of 9.36X, while Hercules Capital trades at a forward P/E of 8.83X, lower than its five-year median of 9.39X [30][33] - Hercules Capital has a return on equity (ROE) of 16.84%, significantly higher than ARCC's 11.05% and the industry average of 11.20% [33][37] - HTGC's dividend yield of 9.23% is slightly higher than ARCC's 8.92%, although both are below the industry average of 10.27% [35][37]